| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2468-1253(20)30250-8 |
| P698 | PubMed publication ID | 32941832 |
| P50 | author | David J. Pinato | Q88654157 |
| P2860 | cites work | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | Q58020775 |
| Controversies in the management of hepatocellular carcinoma | Q89623916 | ||
| Immune-based therapies for hepatocellular carcinoma | Q90208516 | ||
| Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | Q91603429 | ||
| Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study | Q91805716 | ||
| Evolution of Systemic Therapy for Hepatocellular Carcinoma | Q94541665 | ||
| Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Q94659990 | ||
| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Q96165774 | ||
| P433 | issue | 10 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 883-885 | |
| P577 | publication date | 2020-10-01 | |
| P1433 | published in | The lancet. Gastroenterology & hepatology | Q27727626 |
| P1476 | title | Shifting paradigms in the systemic management of hepatocellular carcinoma | |
| P478 | volume | 5 |
Search more.